Pharmaceuticals

Peanut Allergy Treatment Market Forecast 2026–2035: How to Leverage Market Growth

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the peanut allergy treatment market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Peanut Allergy Treatment Market?

The peanut allergy treatment market size has seen rapid expansion in recent years. It is anticipated to grow from $0.5 billion in 2025 to $0.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. In the past, this growth was influenced by the increasing occurrence of peanut allergies in children, the limited success of managing the condition solely through avoidance, a rise in the diagnosis of food allergies, a strong reliance on epinephrine for emergency interventions, and heightened awareness among medical professionals.

The peanut allergy treatment market size is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $0.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. Key factors contributing to this growth during the forecast period include progress in immunotherapy technologies, a rise in approvals for disease-modifying therapies, an increasing need for preventive allergy solutions, the broadening application of biologics aimed at allergic pathways, and intensified investment in food allergy research. Significant trends expected during this period involve the increasing adoption of oral immunotherapy for peanut desensitization, the expanding application of epicutaneous immunotherapy patches, a greater incorporation of biologic therapies in allergy treatment, the development of more pediatric-specific peanut allergy treatments, and an enhanced focus on long-term allergy management solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Which Drivers Are Supporting The Rise Of The Peanut Allergy Treatment Market?

The future expansion of the peanut allergy treatment market is anticipated to be driven by investments in the research and development of allergy treatments. Research and development (R&D) investment pertains to the financial resources allocated by companies, organizations, or governments for activities focused on innovation, product development, and technological progress. Such investment in R&D for allergy treatments is essential for advancing therapies for peanut allergies. This funding promotes the creation of novel immunotherapies and desensitization techniques, which aim to diminish allergic reactions and enhance the quality of life for individuals affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding forms part of a broader $66 million round intended for the development of Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), thereby underscoring its significant potential impact on public health worldwide. Consequently, investment in research and development of allergy treatments is propelling the growth of the peanut allergy treatment market.

What Segments Are Identified Within The Structure Of The Peanut Allergy Treatment Market?

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

Which Trends Are Shaping Activity Within The Peanut Allergy Treatment Market?

Leading companies within the peanut allergy treatment market are concentrating on developing biologic therapies, such as anti-IgE monoclonal antibodies, to provide more targeted and effective solutions for managing peanut allergies, thereby aiming to enhance patient outcomes and their quality of life. Anti-IgE monoclonal antibodies constitute a class of therapeutic agents designed to specifically target and neutralize immunoglobulin E (IgE) antibodies within the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a pharmaceutical company based in Switzerland, obtained approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is designed to mitigate allergic reactions, including anaphylaxis, in patients aged 1 year and older who have IgE-mediated food allergies. The approval was granted based on findings from the NIH-sponsored Phase III OUtMATCH study, which indicated a significant improvement in food allergy tolerance among patients receiving Xolair compared to those administered a placebo.

Which Major Firms Are Strengthening Their Position In The Peanut Allergy Treatment Market?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Peanut Allergy Treatment Market?

North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peanut Allergy Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp

Browse Through More Reports Similar to the Global Peanut Allergy Treatment Market 2026, By The Business Research Company

Peanut Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-treatment-global-market-report

Food Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/food-allergy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795